Literature DB >> 2210990

Intracameral injection of allogeneic lymphocytes enhances corneal graft survival.

S C She1, L P Steahly, E J Moticka.   

Abstract

Failure of corneal grafts is thought to involve the development and activation of specifically sensitized T-cells. One method which might be used to circumvent the development of such cells is the phenomenon of anterior chamber-associated immune deviation (ACAID). Injection of antigen into the anterior chamber of the eye leads to an immune response characterized by normal antibody response coupled with depressed T-cell reactivity especially as measured by delayed-type hypersensitivity. To determine if this phenomenon could be used to alter the course of graft failure, potential recipients (Lewis rats) were injected intracamerally (IC) with allogeneic lymphoid cells (Wistar-Furth). Orthotopic, full-thickness, penetrating keratoplasty was done 0-30 days later, and the recipients were observed for at least 60 days. Approximately 75% of Wistar-Furth corneal grafts placed on uninjected Lewis rats failed as evidenced by continued opacity, edema, and infiltration of mononuclear cells into the grafts. The IC injection of Wistar-Furth lymphocytes decreased this failure rate to 25% and 50% when grafting was done 14 and 7 days after injection, respectively. Grafts of cornea from a third strain onto IC injected animals failed at an intermediate rate which demonstrated some immunologic protection. The results of these studies indicate that IC injection of allogeneic lymphocytes results in prolonged acceptance of corneal grafts syngeneic with the injected lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2210990

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  16 in total

1.  Role of IFN-γ in the establishment of anterior chamber-associated immune deviation (ACAID)-induced CD8+ T regulatory cells.

Authors:  Kathryn Paunicka; Peter W Chen; Jerry Y Niederkorn
Journal:  J Leukoc Biol       Date:  2011-12-16       Impact factor: 4.962

2.  Severing corneal nerves in one eye induces sympathetic loss of immune privilege and promotes rejection of future corneal allografts placed in either eye.

Authors:  K J Paunicka; J Mellon; D Robertson; M Petroll; J R Brown; J Y Niederkorn
Journal:  Am J Transplant       Date:  2015-04-14       Impact factor: 8.086

Review 3.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

4.  Inhibition of corneal allograft reaction by CTLA4-Ig.

Authors:  F Hoffmann; E P Zhang; T Pohl; U Kunzendorf; J Wachtlin; S Bulfone-Paus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-08       Impact factor: 3.117

Review 5.  Immune privilege of corneal allografts.

Authors:  Jerry Y Niederkorn; D Frank P Larkin
Journal:  Ocul Immunol Inflamm       Date:  2010-06       Impact factor: 3.070

6.  Paradigm shifts in the role of CD4+ T cells in keratoplasty.

Authors:  Khrishen Cunnusamy; Peter W Chen; Jerry Y Niederkorn
Journal:  Discov Med       Date:  2010-11       Impact factor: 2.970

7.  Ability of intracamerally inoculated B- and T-cell enriched allogeneic lymphocytes to enhance corneal allograft survival.

Authors:  S C She; E J Moticka
Journal:  Int Ophthalmol       Date:  1993-02       Impact factor: 2.031

8.  Two different regulatory T cell populations that promote corneal allograft survival.

Authors:  Khrishen Cunnusamy; Kathryn Paunicka; Nancy Reyes; Wanhua Yang; Peter W Chen; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-08-11       Impact factor: 4.799

Review 9.  Alloimmunity and Tolerance in Corneal Transplantation.

Authors:  Afsaneh Amouzegar; Sunil K Chauhan; Reza Dana
Journal:  J Immunol       Date:  2016-05-15       Impact factor: 5.422

10.  Immunology of Corneal Allografts: Insights from Animal Models.

Authors:  Jerry Y Niederkorn
Journal:  J Clin Exp Ophthalmol       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.